DALLAS, Feb. 10, 2021 — Reducing the prevalence of obesity may prevent up to half of new Type 2 diabetes cases in the United States, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association. Obesity is a major contributor to diabetes, and…
A treatment, known as KEDRAB (Rabies Immune Globulin [Human]), currently used in the prevention of rabies has been demonstrated to be safe and effective for patients age 17 and under. Results published today in Human Vaccines & Immunotherapeutics report the first and only pediatric trial of any human rabies immunoglobulin (HRIG) currently available in the…
A new paper in Oxford Open Immunology, published by Oxford University Press, examines prior findings in the field of neuroimmunology that suggest potential treatment strategies for patients suffering long-term symptoms from COVID-19. Though COVID-19 was initially believed to be a short-term illness, lasting between one and three weeks, it’s clear that a substantial number of…
Increased level of plasma cells linked to improved cancer survival 1,300 prostate tumor samples studied Immunotherapy-based precision medicine clinical trials being developed CHICAGO— Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits from immunotherapy treatment. A new Northwestern Medicine study discovered the reason appears to be an increase of…
LOS ANGELES (February 10, 2021) — The Lundquist Institute has received a $1.75 million grant from the Steven & Alexandra Cohen Foundation to fund a multi-site clinical trial to evaluate the efficacy and safety of the compound psilocybin in individuals with severe psychological distress associated with a terminal medical illness. The grant will also support…
HOUSTON and San Diego, Calif? The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in…